Literature DB >> 3998750

The long term experience of thymectomy for myasthenia gravis.

G K Scadding, C W Havard, M J Lange, I Domb.   

Abstract

A retrospective survey of the records of 287 patients with generalised myasthenia gravis treated at New End Hospital and later at the Royal Free Hospital by anticholinesterase drugs, with or without thymectomy, between the years 1942 and 1976, shows that 62% of patients were improved. The timing of the operation, the grading of disease and the age and sex of the patient did not greatly influence overall results. The poor diagnosis of thymic tumours was confirmed in this series. A decrease occurred in the number of patients achieving complete remission after 1961, although the proportion of patients improving did not fall. It is possible that anticholinesterase therapy may alter the response to thymectomy.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3998750      PMCID: PMC1028325          DOI: 10.1136/jnnp.48.5.401

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  15 in total

1.  Investigations into thymic disease and tumour formation.

Authors:  G KEYNES
Journal:  Br J Surg       Date:  1955-03       Impact factor: 6.939

2.  An evaluation of thymectomy in myasthenia gravis.

Authors:  J A SIMPSON
Journal:  Brain       Date:  1958-03       Impact factor: 13.501

3.  Surgery of the thymus gland; second (and third) thoughts.

Authors:  G KEYNES
Journal:  Lancet       Date:  1954-06-12       Impact factor: 79.321

4.  MYASTHENIA GRAVIS AND TUMORS OF THE THYMIC REGION: REPORT OF A CASE IN WHICH THE TUMOR WAS REMOVED.

Authors:  A Blalock; M F Mason; H J Morgan; S S Riven
Journal:  Ann Surg       Date:  1939-10       Impact factor: 12.969

5.  The results of thymectomy in myasthenia gravis.

Authors:  G KEYNES
Journal:  Br Med J       Date:  1949-09-17

6.  Study of long-term anticholinesterase therapy. Effects on neuromuscular transmission and on motor end-plate fine structure.

Authors:  A G Engel; E H Lambert; T Santa
Journal:  Neurology       Date:  1973-12       Impact factor: 9.910

7.  A treatment carol: thymectomy revisited.

Authors:  M P McQuillen; M G Leone
Journal:  Neurology       Date:  1977-12       Impact factor: 9.910

8.  Controversies about the treatment of myasthenia gravis.

Authors:  L P Rowland
Journal:  J Neurol Neurosurg Psychiatry       Date:  1980-07       Impact factor: 10.154

9.  Myasthenia gravis: evaluation of treatment in 1,355 patients.

Authors:  V P Perlo; D C Poskanzer; R S Schwab; H R Viets; K E Osserman; G Genkins
Journal:  Neurology       Date:  1966-05       Impact factor: 9.910

10.  Plasma pyridostigmine levels in myasthenia gravis.

Authors:  M C White; P De Silva; C W Havard
Journal:  Neurology       Date:  1981-02       Impact factor: 9.910

View more
  6 in total

1.  Long term treatment of myasthenia gravis with azathioprine.

Authors:  V Fonseca; C W Havard
Journal:  Postgrad Med J       Date:  1990-02       Impact factor: 2.401

2.  Thymectomy for Myasthenia Gravis.

Authors:  Gary S. Gronseth; Richard J. Barohn
Journal:  Curr Treat Options Neurol       Date:  2002-05       Impact factor: 3.598

Review 3.  Effectiveness of thymectomy in non-thymomatous myasthenia gravis: a systematic review.

Authors:  Yan Luo; Deng-Ji Pan; Fei-Fei Chen; Ming-Hui Zhu; Jing Wang; Min Zhang
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2014-12-06

4.  Myasthenia gravis treatment: twelve years experience on 110 patients.

Authors:  G Valli; S Jann; S Premoselli; G Scarlato
Journal:  Ital J Neurol Sci       Date:  1987-12

5.  Actuarial analysis of the occurrence of remissions following thymectomy for myasthenia gravis in 400 patients.

Authors:  L Durelli; G Maggi; C Casadio; R Ferri; S Rendine; L Bergamini
Journal:  J Neurol Neurosurg Psychiatry       Date:  1991-05       Impact factor: 10.154

6.  Thymectomy: role in the treatment of myasthenia gravis.

Authors:  J Spillane; M Hayward; N P Hirsch; C Taylor; D M Kullmann; R S Howard
Journal:  J Neurol       Date:  2013-03-19       Impact factor: 4.849

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.